CEACAM5 and familial pancreatic carcinoma: Chmielewski et al. showed that second-generation anti-CEA CAR-T cells that expressed CD3 and CD28 costimulatory domains persisted long-term in the tumor site, leading to a 67% tumor regression in an orthotopic mouse model of pancreatic cancer (114).